8 results about "Cardioversion" patented technology

The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

The present invention provides a pharmacological wearable cardioverter defibrillation system for conducting cough assisted pharmacological cardioverter defibrillation during onset of a sudden arrhythmia. The system comprises a WCD defibrillator worn by the patient, a drug mix contained either in a reservoir / pump or in an inhaler, and a miniature monitor. The drug mix in the reservoir / pump is equipped with a pump for pumping the drug mix via an indwelling catheter to the coronary sinus while the drug mix in the inhaler is inhaled directly to the lungs. When a sudden arrhythmia is detected by a sensing electrode of WCD, the following steps are carried out: prompting the patient to take the drug mix, prompting the patient to start forceful coughing, and delivering electric shock(s) under either one of the two circumstances that the patient is unable to start coughing or the arrhythmia is not terminated.

The utility model discloses an improved tile type action cardioversion auxiliary device which comprises a bite handle and a fixing cylinder arranged on the rear side of the bite handle, a conveying sleeve is connected to the rear side of the fixing cylinder, a conveying cylinder is connected to the rear side of the conveying sleeve, a connecting pipe is connected to the rear side of the conveying cylinder, and the connecting pipe is connected to the rear side of the fixing cylinder. A monitoring balloon is connected to the exterior of the rear side of the connecting pipe, an adjusting cylinder is arranged on the outer side of the conveying cylinder, and the blowing condition of the patient can be visually displayed through the monitoring balloon. A doctor and a patient can accurately judge the blowing strength and effect by observing the expansion degree of the monitoring balloon, so that the blowing strength is adjusted in time, the accuracy of the cardioversion operation is ensured, and the airflow strength can be accurately adjusted according to the requirements and actual conditions of different patients through matched use of the adjusting cylinder and the adjusting ball. The personalized adjusting function is beneficial to improving the success rate of the cardioversion, so that the treatment is more accurate.

The invention discloses an implantable cardioversion defibrillation system, a medical event prediction method and a medium. The system comprises: a signal acquisition assembly configured to acquire a multi-modal physiological signal; the processor comprises a feature extraction module configured to extract key features from the multi-modal physiological signals to obtain a key feature sequence; the hemodynamics stability model prediction module is configured to process the key feature sequence of the physiological signal to obtain a feature vector sequence; splicing the feature vector sequence of each mode to form a multi-mode comprehensive feature tensor; determining a cross-modal association feature vector based on the association relationship of the multi-modal comprehensive feature tensor; performing feature splicing on the feature vector sequence and the cross-modal association feature vector to generate a fusion feature matrix; based on the fused feature matrix, a haemodynamic instability indicator is predicted. According to the embodiment of the invention, the function of the implantable cardioverter defibrillation system can be enriched.

Disclosed are methods for cardioversion using bundanolol or a pharmaceutical composition comprising bundanolol for cardioversion of patients with paroxysmal or persistent AFib.

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

Electrical medical therapy systems, devices, and methods can employ “electrodes” that are galvanically isolated from target biologic tissue. An electric field can be generated in the biologic tissue via such electrically insulated and galvanically isolated electrodes. Further the electric field can be directionally varied, such as to form a Rotating Electric Field (REF), such that it can impact biological cells from different directions. Directional variation of the electric field can be obtain using a set of three (triad) or more electrodes, or multiple such sets or triads, and applying respective phase-delayed time-varying electric signals to corresponding individual electrodes in the triad or other set of galvanically isolated electrodes. Medical electrical REF therapies can include, among other things, at least one of cardioversion, defibrillation, pacing or other cardiac resynchronization, ablation, cautery, vessel sealing, or thermal sterilization.

The invention disclosed here relates in general to the field of medical devices. In particular, to devices and methods for improving the clinical outcome of patients suffering from cardiac dysrhythmias without cardiac arrest. This method and / or device integrates mechanical, pneumatic, acoustic and / or electrophysiologic capabilities with electrical countershock or pacing capabilities such that the probability of successful cardioversion or pacing is increased. The sequence, forces, and electrical properties of the subsystems can be computer controlled and adjusted in response to biomarker inputs.